AgomAb Therapeutics NV (AGMB)
| Market Cap | 790.02M |
| Revenue (ttm) | n/a |
| Net Income | -84.79M |
| EPS | -3,391.53 |
| Shares Out | 48.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,497 |
| Open | 16.00 |
| Previous Close | 16.02 |
| Day's Range | 15.48 - 16.56 |
| 52-Week Range | 12.66 - 16.65 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 28.00 (0.0%) |
| Earnings Date | Jun 16, 2026 |
About AGMB
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idi... [Read more]
Analyst Summary
According to one analyst, the rating for AGMB stock is "Buy" and the 12-month stock price target is $28.0.
News
Agomab Announces Closing of Initial Public Offering
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapi...
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.
Agomab Announces Pricing of Initial Public Offering
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapi...
AgomAb Therapeutics NV Readies US IPO On Early Promising Results
AgomAb Therapeutics is targeting chronic fibrotic diseases, advancing its lead candidate Ontunisertib in Phase 2a trials for fibrostenosing Crohn's Disease. AGMB's IPO seeks $200 million at a $16.00/s...
Agomab Therapeutics files for US IPO
Biopharmaceutical company Agomab Therapeutics filed for an initial public offering in the United States on Friday.
AgomAb Therapeutics IPO Registration Document (F-1)
AgomAb Therapeutics has filed to go public with an IPO on the NASDAQ